Inhibitors

Inhibitor refers to substance that can hinder the chemical reactions, biological reactions (including immune response) and biological activity. In present time, commonly used inhibitors include immunosuppressants and inhibitors. 1. Immunosuppressive agents: immunosuppressants system refers to drug that can reduce the immune response. It can selectively suppress certain steps of the immune response and immune cells. Immune response refers to the body’s response to a variety of pathogenic substances. Some reactions are favorable to the body and can enhance the body's resistance to disease; some have adverse effects on the body and can cause tissue damage or disorders of physiological functions (allergy). Therefore, patients suffering from allergic reactions being harmful to the body should be subject to the treatment of immunosuppressant to affect the related immune processes and reduce the immune response of the body. For the treatment of various autoimmune diseases and weakening the tissue incompatibility, it has been developed of a variety of immunosuppressive agents, some of which have been widely used in clinical practice. Commonly used immunosuppressants include glucocorticoids (prednisone, prednisolone, etc.), alkylating agents (nitric oxide mustard, cyclophosphamide, thiotepa, busulfan, etc.), and antimetabolites (6- mercaptopurine, azathioprine, methotrexate, etc.). The mechanism of immunosuppressants, though not entirely clear, but is characterized by the following several aspects: ① most kinds of immunosuppressants can simultaneously inhibit cellular and humoral immunity and can be used for organ transplantation and autoimmune disease. ②Its inhibitory effect is strong for the primary immune response while the inhibitory effect against secondary response is weak. ③It can simultaneously act on normal and pathological immunity, therefore, can often lead to some complications. ④These drugs often have strong with serious adverse reactions. 2. Enzyme

Inhibitory effect of topiramasta on neuropathy in db/db mice

Topiroxostat, a selective xanthine oxidoreductase inhibitor, is used in Japan for the treatment of hyperuricemic patients with or without gout.

Jan 9,2024  Inhibitors

4-Aminopyridine Applications and Interactions

4-Aminopyridine (4-AP) is a K+ channel blocker used clinically as symptomatic treatment for demyelinating disorders such as spinal cord injury or multiple sclerosis.

Jan 9,2024  Inhibitors

Synthesis of Tucatinib

Tucatinib was synthesised in a two-step reaction by an aniline fragment. Tucatinib is an orally bioavailable tyrosine kinase inhibitor of human epidermal growth factor receptor-2 (HER2 or ErbB2).

Jan 8,2024  Inhibitors

Tirabrutinib: Synthesis and Introduction

Tirabrutinib is synthesised using 4-phenoxyaniline as a raw material by chemical reaction in the presence of a phase transfer catalyst (TBAB).

Jan 8,2024  Inhibitors

How is Tepotinib Synthesised?

Tepotinib is synthesised through a two-step chemical reaction using acetylbenzonitrile as the raw material.

Jan 8,2024  Inhibitors

Tazemetostat Hydrobromide:Synthesis and Introduction

Tazemetostat Hydrobromide is synthesised using 2- methyl-3-nitrobenzoic acid as a raw material by chemical reaction.

Jan 8,2024  Inhibitors

Synthesis of Surufatinib

Surufatinib is synthesised from dichloropyrimidine and hydroxyindole by substitution reaction. This process requires the participation of Surufatinib Amine.

Jan 5,2024  Inhibitors

How is Selumetinib Sulfate Synthesised?

Selumetinib Sulfate was prepared by a two-step chemical reaction by first synthesising Selumitinib Benzimidazole intermediates using 2,3,4-trifluorobenzoic acid as starting material.

Jan 5,2024  Inhibitors

Selpercatinib: Synthesis and Description

Selpercatinib (LOXO-292) is synthesised using sulfonyl chloride as a raw material by chemical reaction.

Jan 5,2024  Inhibitors

Talazoparib (BMN 673): a polymerase inhibitor

Talazoparib is a PARPi developed by Pfizer and approved in 2018 in USA and 2019 in EU for the treatment of germline BRCA-mutated, HER2-negative breast cancer.

Jan 3,2024  Inhibitors
Prev12345678910...Next>  Go to Page